Oramed Pharma said that the Phase 2b trial is a randomised, double-blind, placebo-controlled, multi-centered study, that primary evaluated the safety, and tolerability of Oramed’s oral insulin delivery technology.
The study took place in five locations throughout South Africa and was monitored by OnQ Consulting, a clinical research organization (CRO) based in Johannesburg, South Africa.
Nadav Kidron, CEO of Oramed, said: “The completion of the Phase 2b clinical trial for ORMD-0801 is a significant milestone for Oramed. We are especially thankful for the dedication of all the investigators who participated in the study.”